FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma.

MLA

Tantisira, Kelan G., et al. “FCER2: A Pharmacogenetic Basis for Severe Exacerbations in Children with Asthma.” The Journal of Allergy and Clinical Immunology, vol. 120, no. 6, Dec. 2007, pp. 1285–91. EBSCOhost, https://doi.org/10.1016/j.jaci.2007.09.005.

APA

Tantisira, K. G., Silverman, E. S., Mariani, T. J., Xu, J., Richter, B. G., Klanderman, B. J., Litonjua, A. A., Lazarus, R., Rosenwasser, L. J., Fuhlbrigge, A. L., & Weiss, S. T. (2007). FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. The Journal of Allergy and Clinical Immunology, 120(6), 1285–1291. https://doi.org/10.1016/j.jaci.2007.09.005

Chicago

Tantisira, Kelan G, Eric S Silverman, Thomas J Mariani, Jingsong Xu, Brent G Richter, Barbara J Klanderman, Augusto A Litonjua, et al. 2007. “FCER2: A Pharmacogenetic Basis for Severe Exacerbations in Children with Asthma.” The Journal of Allergy and Clinical Immunology 120 (6): 1285–91. doi:10.1016/j.jaci.2007.09.005.